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Abstract
Background: Overall therapeutic outcomes of advanced non-small-cell lung cancer (NSCLC) are poor. The
dendritic cell (DC) immunotherapy has been developed as a new strategy for the treatment of lung cancer. The
purpose of this study was to evaluate the feasibility, safety and immunologic responses in use in mature, antigen-
pulsed autologous DC vaccine in NSCLC patients.
Methods: Five HLA-A2 patients with inoperable stage III or IV NSCLC were selected to receive two doses of
5×1 0
7 DC cells administered subcutaneous and intravenously two times at two week intervals. The immunologic
response, safety and tolerability to the vaccine were evaluated by the lymphoproliferation assay and clinical and
laboratorial evolution, respectively.
Results: The dose of the vaccine has shown to be safe and well tolerated. The lymphoproliferation assay showed
an improvement in the specific immune response after the immunization, with a significant response after the
second dose (p = 0.005). This response was not long lasting and a tendency to reduction two weeks after the
second dose of the vaccine was observed. Two patients had a survival almost twice greater than the expected
average and were the only ones that expressed HER-2 and CEA together.
Conclusion: Despite the small sample size, the results on the immune response, safety and tolerability, combined
with the results of other studies, are encouraging to the conduction of a large clinical trial with multiples doses in
patients with early lung cancer who underwent surgical treatment.
Trial Registration: Current Controlled Trials: ISRCTN45563569
Background
Lung cancer is the leading cause of cancer-related mor-
bidity and mortality, resulting in more than 1 million
deaths per year worldwide[1]. In Brazil, the current esti-
matives of incidence are 18.37/100.000 and 9.82/100.000
for men and women, respectively [2]. About 70% of
patients with lung cancer present locally advanced or
metastatic disease at the time of diagnosis, because
there is no efficient method to improve the early diag-
nosis [3] and this fact has a huge impact on treatment
outcomes. In spite of the aggressive treatment with
surgery, radiation, and chemotherapy, the long-term sur-
vival for patients with lung cancer still remains low.
Even patients with early stage disease often succumb to
lung cancer due to the development of metastases, indi-
cating the need for effective approaches for the systemic
therapy of this condition [4].
A variety of novel approaches are now being investi-
gated to improve the outlook for management of this
disease. Theories have also been postulated regarding
the failure of the immune systems to prevent the growth
of tumors. However, despite significant advances in our
understanding of the molecular basis of immunology,
many obstacles remain in translating this understanding
into the clinical practice in the treatment of solid
tumors such as lung cancer [1].
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senting cells with an ability to prime both a primary and
secondary immune response to tumor cells. DCs in
tumors might play a stimulating and protective role for
effector T lymphocytes, and those DCs that infiltrate
tumor tissue could prevent, by co-stimulating molecules
and secreting cytokines, tumor-specific lymphocytes
from tumor-induced cell death [5].
We believe that tumor vaccines may play an adjuvant
role in NSCLC by consolidating the responses to con-
ventional therapy. Then, we decided to conduct this
study to evaluate the feasibility, safety, tolerability and
immunologic responses in use in mature, antigen-pulsed
autologous DC vaccine in a group of non-small cell
lung cancer patients (NSCLC).
Methods
Patient Characteristics
Patients who met the following eligibility criteria were
included: histopathologically confirmed diagnosis of
advanced NSCLC (stage IIIB-IV) [6]; aged ≤70 years;
performance status ≤2 [7]; no prior chemotherapy, sur-
gery, or radiotherapy; no central nervous system metas-
tases and at least one measurable lesion according to
the RECIST’s criteria [8]; no associated acute disease;
HLA-A2 phenotype and expression of WT1 (Wilms
Tumor Protein), HER-2 (Human Epidermal Growth Fac-
tor Receptor 2), CEA (Carcinoembryonic Antigen)o r
MAGE1 (Melanoma Antigen 1) proteins at the tumor
site (tissue). The phenotype HLA-A2 was chosen due
the methodology adopted for the incorporation of the
antigen to the dendritic cell. The maintenance of
organic functions was confirmed by: white blood cells
(WBC) ≥3000/mm
3, neutrophil cells ≥1500/mm
3, hemo-
globin (Hgb) ≥9.0 g/dL, and platelets ≥100,000/mm
3;
bilirubin ≤1.5 mg/dL, aspartate aminotransferase ≤40
IU/L; creatinine clearance >55 mL/minute. The written
informed consent was obtained from all patients
enrolled in the study. The study was conducted in
accordance with the International Conference on Har-
monization (ICH) guidelines, applicable regulations and
the guidelines governing the clinical study conduct and
the ethical principles of the Declaration of Helsinki.
Trial Design
The trial was nonrandomized. All selected patients
received conventional treatment (chemotherapy with or
without radiotherapy). Briefly, the chemotherapy protocols
included paclitaxel 175 mg/m
2 and cisplatinum 70 mg/m
2
on day 1. These cycles were then repeated four times
every 21 days. After the forth chemotherapeutical cycle,
the patients were submitted to computed tomography
(CT) scan of thorax, abdomen and brain to evaluate the
tumor response. The progressive disease was an exclusion
criterion. Patients who met all criteria for inclusion were
eligible to the dendritic cells vaccine as an adjuvant ther-
apy, which was administered after hematological recovery
(platelets ≥70,000/mm
3). The measurable immunologic
r e s p o n s ea n ds a f e t yt ot h ev a c c i n ew e r et h ep r i m a r ya n d
secondary endpoints. The small sample size could pre-
clude meaningful assessment of therapeutic effects. The
clinical tolerability was determined by routine safety
laboratories and the clinical events described by the Can-
cer Therapy Evaluation Program (CTEP), and Common
Terminology Criteria for Adverse Events (CTCAEv3) [9].
The steps of the study are showed in figure 1.
Leukapheresis
Fresenius Com.Tec (Fresenius Kabi - Transfusion Tech-
nology, Brazil) was used for all running procedures of
the MNC program, at 1500 rpm, and with a P1Y kit.
Plasma pump flow rates were adjusted to 50 mL/min.
The volume processed ranged between patients and was
determined by estimated cell count after 150 mL of pro-
cessed blood. ACD-A was the anticoagulant used in
these studies. The Inlet/ACD Ratio ranged from 10:1 to
16:1. There was no need for replacement, because the
total volume of blood taken was less than 15%.
Microbiologic Monitoring
Microbiological tests were performed at the beginning
of the culture, on the fifth day and at the time of vac-
cine delivery. Samples were incubated for 10 days for
the certification of absence of contamination.
Generation of dendritic cells
After informed consent, the mature dendritic cells of
autologous mononuclear cells were isolated by the Ficoll-
Hypaque density gradient centrifugation (Amersham,
Uppsala, Sweden). Monocytes were then enriched by the
Percoll hyperosmotic density gradient centrifugation fol-
lowed by two hours of adherence to the plate culture.
Cells were centrifuged at 500 g to separate the different
cell populations. Adherent monocytes were cultured for
7 days in 6-well plates at 2 × 10
6 cells/mL RMPI medium
(Gibco BRL, Paisley, UK) with 1% penicillin/streptomy-
cin, 2 mM L-glutamine, 10% of autologous, 50 ng/mL
GM-CSF and 30 ng/mL IL-4 (Peprotech, NJ, USA ). On
day 7, the immature DCs were then induced to differenti-
ate into mature DCs by culturing for 48 hours with 30
ng/mL interferon gamma (IFN-g).
According to the previous expression detected by
immunohistochemistry, the HLA-A2 restricted to WT1
peptide (RMFPNAPYL), CEA peptide (YLSGANLNL),
MAGE-1 peptide (KVAELVHFL), and HER-2 peptide
( K I F G S L A F L )w e r ep u l s e dt ot h eD Cc u l t u r e( d a y9 )a t
the concentration of 25 ug/mL and incubated for 24
hours to the vaccine administration.
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DC were harvested on day 7 and washed with PBS.
Fluorescent conjugated monoclonal antibodies targeted
against the following antigens were used for phenoty-
pic analysis: CD14 (PerCp), CD80 (Pe), CD83 (APC),
CD86 (Fitc), HLA-A (Fitc), HLA-DR (Pe-Cy7), CD11c
(Pe), CD40 (PerCp-Cy5.5), CCR5 (Pe), CCR7 (Fitc), IL-
10 (Pe) and IL-12p70 (Fitc) (Caltag, Burlingame, CA,
USA). Antibodies targeted against CD3 (Pe), CD8 (PE-
Cy7), CD4 (PerCp) and IFNg (Fitc) were used for phe-
notypic analysis of lymphocyte after the lymphoproli-
feration assay. Isotype-matched antibodies were used
as controls (Caltag, Burlingame, CA, USA). The label-
ing was carried out at room temperature for 30 min-
utes in PBS. For the intracellular labeling (IL-10 and
IL-12p70), cells were permeabilized and fixed using the
Fix-Cells Permeabilization Kit (Caltag, Burlingame, CA,
USA). After labeling, cells were washed twice in PBS
and analyzed by a FACSArea cytometry using the
CELL QUEST PRO software application. The DC and
lymphocyte populations were gated based on their for-
ward-scatter and side-scatter profile (large or small
granular cell population, respectively). The results are
expressed as percentage of positive cells and for IL-12
and IL-10 expression, the mean fluorescence intensity
was also observed.
CFSE Labeling
PBMCs (1 × 10
7) were incubated at 37°C for 15 min in
1 mL of PBS containing CFSE (Molecular Probes Eur-
ope, Leiden, The Netherlands) at 0.6 μM, a concentra-
tion which was determined in preparatory experiments
as useful. After one washing step in PBS containing 1%
FCS, the cells were re-suspended at a density of 1 × 10
6
cells/mL and used to perform the lymphoproliferation
assay. After 6 days of incubation, the CFSE-labeled cells
were washed once in PBS and then either immediately
fixed in PBS containing 4% formaldehyde, and subjected
to analysis by a FACSArea and CellQuest software (BD,
Mountain View, CA, USA). The CFSE-fluorescence was
plotted against forward scatter. The retained bright
CFSE staining consistent with no proliferative response
and the lost CFSE-fluorescence indicated an induced
proliferation. The reduced level of CFSE staining in the
stimulated lymphocyte in relation to the unstimulated
was used to calculate a proliferation index.
Immunization Protocol
A prime vaccine and a single boost were given fifteen
days apart. For each dose of vaccine, two aliquots were
prepared in separated syringes with saline solution (500
μl/dose) containing 5 × 10
7 cells. First, a dose was sub-
cutaneously administered in the arm and after 1 hour
t h es e c o n dd o s ew a sg i v e ni n t r a v e n o u s l yi nt h eo t h e r
arm. After the second dose, the patient remained under
observation for 1 hour for evaluation of immediate
unexpected adverse events.
Clinical Evaluation
The follow-up included routine history and physical
exam, chest x-ray and computed tomography scans at
regular intervals post immunization or as directed by
signs or symptoms of tumor recurrence.
Immunologic Assessment
A. Phenotypic characterization of immune cells from
patients’ peripheral blood
The cellular composition of the immune system, before
and after vaccination with the dendritic cells, was
assessed from peripheral blood samples using flow cyto-
metry. The day of immunization was considered as “Day
0”. The peripheral blood samples were collected one
week before vaccination ("Day -7”), two weeks after the
first dose of vaccine ("Day 14”), two weeks after the sec-
ond dose of vaccine ("Day 28”) and one month ("Day
43”) after the end of the vaccination protocol.
 
 
 
 
D-7 
2 Months  2 Months  1 Month 
D43  D28  D14  D7  D0 
1 Month 
Dx+S1 S2 V S3 S4 Sn PD 
CH/RT
V  L L
Figure 1 The steps of the study. Leukapheresis’ day is marked with “L” (D-7 and D7). Immunizations’ day is marked with “V” (D0 and D14). Blue
triangle - Evaluation step: “Dx+S1” = Diagnosis and 1
st Radiologic Staging; “S2” =2
nd Radiologic Staging (1 month after conventional treatment);
“S3” =3
rd Radiologic Staging (1 month after vaccine); “S4...Sn” = Radiologic staging was repeated every 2 months until the progression of the
disease ("PD” - black triangle). Red triangle - Conventional treatment (chemo/radiotherapy). Green triangle - Lymphoproliferation test; it was done
before immunization on D0 and D14.
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for T lymphocytes (CD4 and CD8), NK cells (CD56), B
lymphocytes (CD19) and mature dendritic cells (CD86,
CD80, CD83, CD40 and HLA-DR) were used for immu-
nophenotyping of the patients’ blood cells.
Approximately 2 × 10
5cells per test were treated with
a lysis solution for the red blood cells, centrifuged at
300 g for 5 minutes, rinsed with PBS and re-suspended
in 100 μl of cytometry buffer (PBS with 0.5% bovine
serum albumin and 0.02% sodium azide). Subsequently,
these cells were incubated in the dark for 30 minutes at
4°C with monoclonal antibodies labeled with the specific
fluorochromes described above. Then the samples were
washed twice with flow cytometry buffer, fixed with par-
aformaldehyde and analyzed by a flow cytometer (FACS-
Calibur - Becton Dicknson).
B. Analysis of the specific immune response in vitro by flow
cytometry
The lymphoproliferation test was used to assess the abil-
ity of dendritic cells to stimulate specific lymphocytes in
vivo.
C. Collection of T lymphocytes
The peripheral blood samples collected at the times
describes above were enriched with T lymphocytes
(CD3
+) by negative immune selection with immunomag-
netic beads specific for NK cells (CD56
+), B lymphocytes
(CD19
+) and monocytes (CD14
+).
The cells collected before vaccination were centrifuged
at 600 g during 10 minutes and the cell pellet was
washed twice with PBS, re-suspended in RPMI with 1%
human AB serum and 10% dimethyl sulfoxide and then
frozen to -90° C at a controlled rate of 1° C/minute
until the time of the first test (two weeks after the first
dose of the vaccine).
D. Lymphoproliferation assay
The T cells (1 × 10
6cels/mL) were re-suspended in 1
mL of PBS containing 0.25 μM of CFSE (Molecular
Probes, The Netherlands) and incubated for 15 minutes
at 37°C. After this incubation period, the cells were
washed twice with RPMI 1640 supplemented with 1%
human AB serum cold by centrifugation at 600 g for 10
minutes and incubated in ice for 5 minutes.
After this period, the cells were again centrifuged at
600 g for 10 minutes and re-suspended in the same
medium supplemented with 25 ng/mL of IL-7. These
lymphocytes were cultivated in 24-well plates (1 × 10
5
cells/well) with 25 μg/mL of each tumor peptide defined
for each patient, separately. This culture was incubated
for 4 days at 37°C in 5% CO2.
The percentage of proliferation was calculated using
the number of cells with CFSE labeling using the follow-
ing formula: [(Number of CFSE-labeled cells in the test
group - Number of CFSE-labeled cells in the control
group)/Number of CFSE-labeled cells in the control] ×
100. As for the control, the same test was performed
using unstimulated lymphocytes labeled with CFSE. All
tests had been carried out in triplicate.
The results of the lymphoproliferation were compared
using Wilcoxon signed ranks test.
Results
Patient Characteristics
Between June/2006 and August/2008, 48 patients were
evaluated. Only five patients met all criteria for inclu-
sion in the study. The median age was 60 years and 3 of
5 patients were males. The histologic subtypes were as
follows: adenocarcinoma (2), invasive mucinous adeno-
carcinoma (former bronchioloalveolar) (1), squamous
cell carcinoma (1) and adeno/squamous cell carcinoma
(1). Four patients were stage IIIB and one was stage IV
at the time of the diagnosis. The patients’ characteristics
are summarized in Table 1.
Safety
During the chemo and radiotherapy, no adverse events
grade >2 were reported. No reaction was observed dur-
ing or after the leukapheresis. No local reaction was
o b s e r v e da tt h ev a c c i n es i t eo f application. One patient
presented systemic reactions after the immunotherapy.
This patient developed fatigue (grade 2) and chills five
days following the first dose of the vaccine and was hos-
pitalized on the 7
th day because the laboratorial analyses
showed leukopenia (1,500/mm
3;g r a d e3 ) ,g r a n u l o c y t o -
penia (900/mm
3;g r a d e3 ) ,l y m p h o p e n i a( 4 9 5 / m m 3 ;
grade 3); thrombocytopenia (88,000/mm3; grade 1); ane-
mia (hemoglobin 8,5 g/dL; grade 2) and hyponatremia
(126 mEq/L; grade 3). The serology to the Human Immu-
nodeficiency Virus (HIV), mononucleosis, cytomegalo-
virus, Epstein Barr, Mycoplasma pneumoniae and dengue
were negatives, as well as the bacterial cultures. Cephe-
pime was prescribed empirical l y .N oc o l o n y - s t i m u l a t i n g
factor was used and the patient recovered from blood
changes, spontaneously, after five days, except by the
anemia. The hyponatremia was treated with sodium
replacement and became normal after one week.
Immunologic responses to Vaccines
The lymphoproliferation assay showed an improvement
in the specific immune response after the immunization.
This response was not long lasting and a tendency to
reduction 2 weeks after the second dose of the vaccine
was observed.
Patterns of reactivity ranged between individuals
(Figure 2). Two patients (#3 and #5) expressed a note-
worthy result at the lymphoproliferation tests at one
time point after the first dose. Patients #1 and #4 pre-
sented a visibly boosted response temporally related to
the second dose. Patient #2 showed a mixed response
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Patient
ID
Sex Age Histology Stage at
enrollment
ECOG* Expression Therapy
Sequence
Time between
the treatment
modalities
(days)
Response to the
conventional
treatment
(RECIST)
Time to
progression
from
Chemotherapy
(days)
Time to
progression
from
Immunotherapy
(days)
Survival
from
Diagnosis
(days)
Survival from
Immunotherapy
(days)
1 M 61 Sq/Ad IIIB (T4,N2) 1 HER-2 (grade 3)
MAGE1 (grade
5)
CT - IT 77 Partial Response 138 47 258 84
2 M 66 Ad IIIB (T2,N3) 2 WT1 (grade 4)
CEA (grade 6)
CT - IT - XRT 38; 3 Stable disease 112 60 358 198
3 M 59 Ad IIIB (T4,N2) 1 CEA (grade 7) CT - XRT - IT 30; 52 Stable disease 231 82 276 112
4 F 63 IMA IV (T4,N2,
M1)
#
2 WT1 (grade 2)
CEA (grade 7)
HER-2 (grade 1)
CT - IT - CT 45; 56 Stable disease 64 1 329 82
5 F 50 Sq IIIB (T4,N2) 1 CEA (grade 3)
HER-2 (grade 2)
CT - XRT - IT 51; 56 Partial Response 200 22 560 277
Sq, squamous cell carcinoma; Ad, adenocarcinoma; IMA, invasive mucinous adenocarcinoma.
*ECOG: Eastern Cooperative Oncology Group performance status.
#T4Ipsi Nod, N2,M1aCont Nod.
P
e
r
r
o
u
d
e
t
a
l
.
J
o
u
r
n
a
l
o
f
E
x
p
e
r
i
m
e
n
t
a
l
&
C
l
i
n
i
c
a
l
C
a
n
c
e
r
R
e
s
e
a
r
c
h
2
0
1
1
,
3
0
:
6
5
h
t
t
p
:
/
/
w
w
w
.
j
e
c
c
r
.
c
o
m
/
c
o
n
t
e
n
t
/
3
0
/
1
/
6
5
P
a
g
e
5
o
f
8with a strongest response after the first dose to WT1
and a boosted response to CEA.
All the results of the lymphoproliferation assay - all
patients and all antigens - are showed in Figure 3.
These results were compared using Wilcoxon signed
ranks test. The difference between “D-7” and “D1 4 ”
was not significant (p = 0.135). However, the difference
was significant between “D- 7 ” and “D2 8 ” (p =0 . 0 0 5 )
and between “D- 7 ” and “D4 3 ” (p = 0.002).
Clinical outcomes
The clinical follow-up was available for all individuals
for a minimum of 8.5 months from the diagnosis and
almost 3 months from de second dose of immunother-
apy. Data are presented in Table 1. Two individuals had
partial response to the conventional therapy, while three
had a stable disease. All of them received chemotherapy
and those three were submitted to radiotherapy as well.
Patient #2 underwent immunotherapy previous to the
radiotherapy. From the last dose of the vaccine, the time
to the disease progression and survival ranged between
1 to 82 and 82 to 277 days, respectively. One day after
immunotherapy, the Patient # 4 presented worsening of
the cough accompanied by progressive dyspnea. The fol-
l o wu ps h o w e dp r o g r e s s i v ed i s e a s eo nt h er a d i o l o g i c
exams.
Discussion
Despite the developments on chemo and radiotherapy,
the 5 year survival rate improved only 3% (13 to 16.2%)
between 1975 and 2002 [10]. This fact occurs mainly
because there is not an efficient screening method for
 
 
 
Figure 2 Immunological response. Lymphoproliferation index: “D
-7” (1 week before 1
st dose); “D1 4 ” (2 weeks after 1
st dose); “D2 8 ”
(2 weeks after 2
nd dose); “D4 3 ” (4 weeks after 2
nd dose); HER,
human epidermal growth factor receptor; MAGE, melanoma
antigen; CEA, carcinoembryonic antigen; WT1, Wilms tumor protein;
P1, patient 1; P2, patient 2; P3, patient 3; P4, patient 4; P5, patient 5.
Figure 3 Immunological response. Lymphoproliferation’sr e s u l t s
from all patients and all antigens were compared using Wilcoxon
signed ranks test. “D- 7 ” (Median = 1.33; Min = 0.81; Max = 3.59); “D
14” (Median = 1.42; Min = 0.44; Max = 7.90); “D2 8 ” (Median = 2.86;
Min = 1.13; Max = 4.68); “D4 3 ” (Median 2.13; Min = 0.72; Max =
4.10). The difference was significant between “D- 7 ” and “D2 8 ”
(*p = 0.005) and “D-7” and “D-43” (**p = 0.002).
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Page 6 of 8the early diagnosis and it also shows that new therapeu-
tic modalities are necessary.
Based on the antigen specificity of the immune system
and the safety profile of cancer vaccines, the effective
immunotherapy would be an ideal adjuvant, following
initial clinical responses to definitive therapy [11]. The
antigen-presenting cells, like dendritic cells, play an impor-
tant role in the induction of an immune response, and an
imbalance in the proportion of macrophages, immature
and mature dendritic cells within the tumor could signifi-
cantly affect the immune response to cancer [4].
Even though there have been numerous clinical trials
for various types of cancer, there are few DC vaccines
trials in patients with lung cancer, and many aspects
related to the immunotherapy - like maximum dose,
administration schema, response and safety - are
unknown.
Our study was done with two aliquots of 5 × 10
7 cells
for each dose. This dose is similar to that of other stu-
dies that used doses ranging between 8.2 and 10 × 10
7
cells [11-13]. Another trial demonstrated that a dose of
1.2 × 10
7 cells did not reach a truly maximum tolerated
dose [14]. Given that there is no clear consensus about
whether or not the route of immunotherapy influences
o nt h ee f f i c a c yo ft h ev a c c i n e ,w ec h o s et oa p p l yi tb ya
subcutaneous and intradermal route.
In addition to the high level dose, the vaccine was
well-tolerated as noted in many studies [11-15], even in
a study in Hepatitis C Virus (HCV) infected individuals
[16]. We observed no local reaction, but one patient
presented fatigue, chills, pancytopenia and hyponatremia
five days after the first dose of the vaccine. Usually, the
reactions after immunotherapy occur within 24-48
hours after the infusion [12,17]. Therefore, we hypothe-
size that the patient developed an infection, but it can-
not be proved because the bacterial cultures and viral
tests were negatives.
Three patients had a longer time survival than expect
for their TNM stage. Two of these (patients #4 and #5)
had a survival almost twice greater than the expected
average and they were the only ones that expressed HER-
2 and CEA together. Although the small sample size pre-
cludes the meaningful assessment of the therapeutic
effects and any results may be due to chance, we cannot
exclude that these clinical outcomes may indicate some
therapeutic efficacy. Many variables related to the host
and the vaccine may be important to reach therapeutic
efficacy. The immunologic resistance of a tumor to
immune effector cells at the local level remains a poten-
tial limitation to the vaccine efficacy, and the choice of
antigens is also relevant to the therapeutic efficacy and
potentially to the immunologic responses to vaccines
[12]. Furthermore, the characteristics of the tumor
antigen may change and it can become unresponsive to
the initial tumor-antigen targeted therapy as tumors
grow during conventional therapy [14,15]. We decided to
produce a multivalent vaccine according to each patient
tumor’s antigen expression, observed by immunohisto-
chemistry, to avoid this phenomenon and improve the
results of immunotherapy by inducing a broad repertoire
of antigen-specific T cells [15]. Indeed, the profile of anti-
gens with better therapeutic responses has not yet been
determined.
The patterns of reactivity ranged between individuals
(Figure 2). Two patients expressed a significant immu-
nologic reaction after the first dose; another two pre-
sented a boosted response after the second dose and
one showed a mixed response. The lymphoproliferation
assay showed an improvement in the specific immune
response after the immunization (Figure 3). However,
this response was not long lasting and a tendency to
reduction 2 weeks after the second dose of the vaccine
was observed. This finding is consistent with other stu-
dies that showed a booster response to subsequent
immunization [11,12]. The trend to return to baseline
after an increase of reactive T cells might be viewed as a
transient response [11], associated to the immunosup-
pressive environment within a tumor mass. It turns the
vaccination protocol into a tiresome activity given that
multiples doses may be required to reach clinical
efficacy.
Conclusion
Despite the small sample size, the results on the
immune response and safety, combined with the results
from other studies, are encouraging to the conduction
of a clinical trial with multiples doses in patients with
early lung cancer who underwent surgical treatment.
The DC vaccine could be a hopeful adjuvant therapeutic
modality for this group of patients because they do not
present a gap to antigenic changes or a bulky disease.
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